• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Haemonetics drops $60 million on GlobalMed, posts Q3 gains

Haemonetics drops $60 million on GlobalMed, posts Q3 gains

February 1, 2010 By MassDevice staff

Haemonetics Corp. (NYSE:HAE) is expanding its reach into hospital and blood center management, announcing a definitive agreement to pay $60 million for a California-based healthcare software company.

Company executives said the deal — the company’s fourth in less than a year — for GlobalMed Technologies Inc. should significantly expand Haemonetics’ offerings for blood-collection centers with little overlap of its existing business. The acquisition also should broaden Haemonetics’ presence in Europe and Asia, they said.

Global Med’s domestic operations include Wyndgate Technologies, supplying software products and services to donor centers and hospital transfusion services; eDonor, a web-based donor relationship management system; and PeopleMed, offering validation, consulting and compliance software. The company also operates an European subsidiary, Inlog SA, providing cellular therapy software in addition to donor center and transfusion management tools.

“At its core, effective blood management is software,” Haemonetics CEO Brian Concannon said during a Feb. 1 conference call discussing the deal and fiscal third-quarter results for the Braintree, Mass.-based company.

With $8 million in revenues during the three months ended Dec. 31, 2009, software solutions currently comprises only about 5 percent of Haemonetics’ total business, although the GlobalMed acquisition should nearly double segment revenues in future quarters. Through the first nine months of 2009, GlobalMed generated $1.6 million in net income on $23.7 million in revenues.

Overall, Haemonetics reported an $18 million profit during the quarter, on $165 million in revenues. Growth was strongest in the company’s plasma disposables segment, rising 10 percent from year-ago levels to $59 million. During the conference call, company officials said they expect the plasma business will continue to drive Haemonetics’ growth, benefiting from rising market share and price improvements as well as an expanding market.

Haemonetics plans to soon launch a formal tender offer for GlobalMed shares, offering $1.22 per common share, with the transaction slated to close by the end of March. Concannon said the company should have about $100 million in cash on hand after the deal is completed.

Filed Under: Blood Management, Business/Financial News, News Well, Software / IT Tagged With: GlobalMed Technologies, Haemonetics

More recent news

  • Data backs DermaSensor skin cancer detection device
  • GE HealthCare expands digital imaging portfolio with enhanced MIM Encore software
  • Accelus wins FDA clearance for MRI compatibility of FlareHawk spinal implants
  • Presidio wins FDA IDE for ultra-low frequency neuromod, hires new CFO
  • Epiminder study backs implantable EEG tech

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy